Astellas Pharma Gmbh

Astella Pharma Inc.

Chikashi Saitoh

Akio Kakefuda

Kentaro Sato

Jun Maeda

Hiroyuki Koshio

Takahiro Ishii

Takashi Sugane

Issei Tsukamoto

Takatoshi Kanayama

Tatsuhisa Takahashi

Seijiro Akamatsu

Jotaro Suzuki

Fumie Narazaki

Chisato Kanai

Takahiro Kuramochi

A novel pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound and its pharmaceutically acceptable salt has a potent FAAH-inhibitory activity. Further, the pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound of the present disclosure is also useful in the treatment of urinary frequency and urinary incontinence, overactive bladder and/or pain.

Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound

To provide a compound usable for treatment of diseases associated with fatty acid amide hydrolase (FAAH), especially for treatment of urinary frequency and urinary incontinence, overactive bladder and/or pain. We have found that a novel pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivative and its pharmaceutically acceptable salt has a potent FAAH-inhibitory activity. Further, the pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivative of the present invention has an excellent effect for increasing an effective bladder capacity, an excellent effect for relieving urinary frequency and an excellent anti-allodynia effect, and is therefore usable for treatment of urinary frequency and urinary incontinence, overactive bladder and/or pain.

A novel pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound or its pharmaceutically acceptable salt has a potent FAAH-inhibitory activity. Further, the pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound of the present disclosure is also useful in the treatment of urinary frequency and urinary incontinence, overactive bladder and/or pain.

A novel 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or a pharmaceutically acceptable salt thereof, which is useful as an agent for treating or preventing nocturia and/or diabetes insipidus, is provided.

4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or salt thereof

4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivative or salt thereof

4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivatives, which have excellent arginine vasopressin Vactivity and are useful for a drug for the treatment of central diabetes insipidus and/or nocturia.

4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivatives or salts thereof

Growing community of inventors

Tokyo, Japan

Chikashi Saitoh